BIOLARGO, INC. – What You Need to Know

Thinking about investing in BioLargo? It is a fascinating company, but before you put your money on the line, let’s look at what is happening under the hood. Here is the breakdown in plain English.

1. What does this company actually do?

Think of BioLargo as a problem-solving incubator. They invent and sell technologies across four main areas:

• Water Treatment: Their flagship technology, the Aqueous Electrostatic Concentrator (AEC), is designed to remove "forever chemicals" (PFAS) from water.
• Odor and VOC Control: Their subsidiary, BioLargo Water, sells the CupriDyne Clean line. This neutralizes odors and harmful gases for industrial and city clients.
• Advanced Materials: They are developing sulfur-based battery parts aimed at making lithium-sulfur batteries more powerful and cheaper to produce.
• Engineering Services: Their subsidiary, BLEST, provides research and engineering services to other companies, helping clients develop and scale their own products.

2. How do they make money?

BioLargo uses a mix of income sources:

• Product Sales: Selling odor control products and water treatment equipment.
• Service Fees: Earning revenue through consulting, lab testing, and engineering design.
• Licensing: Aiming to earn royalties by letting other companies pay to use their patented technologies.

The Reality Check: BioLargo is in a "growth phase." This means they spend much more than they earn and are not yet profitable. They rely on selling more shares and taking on debt to pay for research and daily operations.

3. The "Going Concern" Warning

This is the most important update for any investor: BioLargo’s auditors have issued a "going concern" warning. This means there is real doubt about whether the company has enough cash to pay its bills over the next 12 months. They are effectively living paycheck to paycheck, and their survival depends entirely on their ability to raise more money from investors.

4. The "Hidden" Risks

• The "Penny Stock" Trap: Because the stock trades at a low price and is not on a major exchange, it is considered a "penny stock." This makes it harder to buy or sell shares quickly at the price you want.
• Dilution: To pay bills, BioLargo often pays staff and consultants with stock instead of cash, and they issue new shares to raise capital. In 2025, they issued 16 million new shares. Every time they do this, your ownership percentage of the company shrinks.
• No Dividends: The company has never paid a dividend and plans to keep all future earnings to fund growth. You only make money if the stock price goes up, which is never guaranteed.
• The "Legal Headache": BioLargo is in a major legal fight with their former top customer, Pooph Inc. This conflict has hurt the company’s financial health, contributing to a 56% drop in 2025 revenue.
• Cybersecurity: As a tech firm, they hold sensitive data. A data breach could cost them their intellectual property, damage their reputation, and create legal bills they cannot afford.

Final Thoughts for Investors

Investing in companies that are still "figuring it out" is extremely risky. With a "going concern" warning, the difficulty of trading penny stocks, and constant dilution, this is not a typical investment.

Before you buy:

• Check your risk tolerance: Only use money you are 100% comfortable losing.
• Look for milestones: Watch for official announcements regarding new licensing deals or profitability—these are the only things that will likely change the company's financial trajectory.
• Read the filings: If you are serious, look at their latest 10-K or 10-Q filings on the SEC website to see the most recent updates on their cash position.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice.